(19)
(11) EP 1 441 720 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.03.2012 Bulletin 2012/13

(45) Mention of the grant of the patent:
04.01.2012 Bulletin 2012/01

(21) Application number: 02782236.0

(22) Date of filing: 24.10.2002
(51) International Patent Classification (IPC): 
A61K 31/403(2006.01)
A61P 31/12(2006.01)
C07K 5/103(2006.01)
 A61K 31/497(2006.01)
C07D 403/12(2006.01)
(86) International application number:
PCT/US2002/034248
(87) International publication number:
WO 2003/035060 (01.05.2003 Gazette 2003/18)

(54)

INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM

HEMMER VON SERIN-PROTEASE, INSBESONDERE VON HEPATITIS-C-VIRUS-NS3-NS4A-PROTEASE, MIT EINEM KONDENSIERTEN RINGSYSTEM

INHIBITEURS DE LA SERINE PROTEASE, EN PARTICULIER DE LA PROTEASE NS3-NS4A DU VIRUS DE L'HEPATITE C, INTEGRANT UN SYSTEME DE CYCLES ACCOLES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

(30) Priority: 24.10.2001 US 343862 P

(43) Date of publication of application:
04.08.2004 Bulletin 2004/32

(60) Divisional application:
10178006.2 / 2402009

(73) Proprietor: VERTEX PHARMACEUTICALS INCORPORATED
Cambridge, MA 02139-4242 (US)

(72) Inventors:
  • PERNI, Robert, B.
    Marlborough, MA 01752 (US)
  • PITLIK, Janos
    Westborough, MA 01581 (US)
  • VAN DRIE, John, H.
    Andover, MA 01810 (US)
  • FARMER, Luc, J.
    Foxboro, MA 02035 (US)

(74) Representative: Minderop, Ralph H. 
COHAUSZ & FLORACK Patent- und Rechtsanwälte Partnerschaftsgesellschaft Bleichstrasse 14
40211 Düsseldorf
40211 Düsseldorf (DE)


(56) References cited: : 
WO-A-01/74768
 WO-A-02/08244
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).